Robin Taylor

Robin Taylor serves as the Chief Commercial Officer at Agenus since July 2023 and concurrently contributes as a member of the Scientific Advisory Board at Senti Biosciences, where the focus is on developing innovative cell and gene therapies. As the owner of Taylor Global Biopharma Consulting since March 2020, Robin provides strategic consulting rooted in over twenty years of experience in commercial and drug development, particularly within oncology. Previous roles include Chief Commercial Officer at Seattle Genetics and Vice President at AstraZeneca, where significant responsibilities included leading global product strategies for major oncology products at Genentech, such as Tecentriq and Avastin. Robin holds an MBA from the University of California, Berkeley, a Ph.D. in Molecular Genetics from the University of Toronto, and a B.Sc. in Biochemistry and Mathematics from The University of British Columbia.